Kairos Pharma (KAPA) : 4-month performance

Ticker: KAPA

Kairos Pharma (KAPA) began trading on the NYSE on Mon 16 Sept 24

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. 

• Sector(s): Healthcare
• Industry: Biotechnology
• Formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016
• Incorporated in 2013 
• HQ in Los Angeles, California.
• https://kairospharma.com

KAPA

Kairos Pharma (NYSEMKT:KAPA) priced on Monday its initial public offering of 1.5M shares of common stock at a public offering price of $4 per share. The gross proceeds from the offering are expected to be $6.2M.

 

IPOs this week : June 17 - 21, 24 (wk 25)

IPOs expected to price

• Nova Minerals (OTCQB:NVAAF), an Australian-listed mining exploration stage company, is expected to start trading on the New York Stock Exchange on Tuesday. The company is offering 888.9K American depositary shares at a price of $9/share. 
• Chinese office supplier and after-sale maintenance and repair services provider Eshallgo (EHGO)
• Clinical-stage biopharmaceutical firm Kairos Pharma (KAPA). 

IPO quiet period expirations

• NANO Nuclear Energy (NNE), 
• Silvaco Group (SVCO), and 
• Proficient Auto Logistics (PAL).